FARE - Food Allergy Research & Education Logo

Study to Assess Tolerance of Traces in Peanut/Tree Nut Allergic Children.

Study Purpose

This protocol will help better define whether patients with peanut and/or tree nut food allergy can tolerate traces in products with precautionary allergen labelling.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Yes
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 2 Years - 18 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Children aged 2-18 years at time of inclusion.
  • - Tree nut or peanut allergy documented by: - Positive skin prick tests (SPTs) to peanut and/or tree nuts.
  • - Positive specific IgE (sIgE) to peanut and/or tree nuts ( ≥0.35 kU/L) - A recent (< 1 year) positive food challenge, reacting to the dose of 30 mg of proteins or below.
  • - Parent/Legal guardian has been informed about the study and has signed Informed Consent Form.

Exclusion Criteria:

  • - History of a moderate or severe reaction during a food challenge with a dose of 30 mg of proteins or less.
  • - Expected non-adherence to the study protocol.
  • - Severe or uncontrolled asthma.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03680066
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

N/A
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

University Hospital, Geneva
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Philippe Eigenmann, MD
Principal Investigator Affiliation University Hospitals of Geneva
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries Switzerland
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Food Allergy, Peanut Allergy, Tree Nut Allergy
Additional Details

Visit 1 (V1): During this visit at the Pediatric Research Platform at the Children's Hospital, subjects will undergo an open food challenge to 3 processed foods labeled with "may contain traces" by following safety and accuracy guidelines for food challenges (7). The following foods (similar for all patients) will be given in one dose in the size of a regular serving:

  • - cookies, max 30 g; - chocolate, max 30 g; - breakfast cereals, max 50 g.
Each meal will be administered with a 1 hour observation period in between and at the end. If the patient does not react to any of the foods or has only oral itching (mild symptoms), he/she will be instructed to stop the ban on "may contain" foods and eat them regularly. If the patient has more than mild symptoms, the study will be stopped and the patient will be banned from eating foods with traces. The study subjects with a negative challenge and instructed to eat foods with the "may contain" label will be provided emergency medications and instruction on when and how to use them according to current guidelines (8). An age appropriate quality of life questionnaire will be filled out by the parents/patient during the visit. For the following 3 months after "may contain food" challenges, the patients will be invited to eat on a regular basis any foods labeled as "may contain" tree nuts and/or peanuts and record the consumption on a diary. Such foods will only be eaten in presence of a family member instructed for the measures to be taken in case of a reaction. They will record any history of reaction and contact the study team. The brand name of the food, and if available the batch will be recorded. The participants will store the study food and its packaging safely in a box and bring it along at V2 for allergen content analysis. If a reaction occurs, the food will be analyzed for allergen content by immunoaffinity capillary elecrophoresis-matrix assisted laser desorption/ionization mass spectrometry, as well as a simplified version of this technique, the immunomagnetic separation -matrix-assisted laser desorption/ionization mass spectrometry. Visit 2 (V2): During this visit, the parents/patients will report on the brand, the frequency and the amount of "may contain" foods eaten since V1. The quality of life questionnaire will be filled out again by the parents/patient.

Arms & Interventions

Arms

Experimental: Foods with traces

Oral food challenge with foods with traces

Interventions

Other: - Oral food challenge to foods with traces

Subjects will undergo an open food challenge to 3 processed foods labeled with "may contain traces". The following foods (similar for all patients) will be given in one dose in the size of a regular serving: cookies, max 30 g; chocolate, max 30 g; breakfast cereals, max 50 g. Each meal will be administered with a 1 hour observation period in between and at the end.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Geneva, Switzerland

Status

Recruiting

Address

Pediatric Allergy Unit - University Hospitals of Geneva

Geneva, , 1205

Site Contact

François Graham, MD, MSc

francois.graham@hcuge.ch

079 55 35215

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.